Promising combo tackles rare stomach cancer before and after surgery
NCT ID NCT07178340
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 32 times
Summary
This study tests a combination of chemotherapy drugs and an immunotherapy drug (sintilimab) given before and after surgery for a rare type of stomach cancer called HER2-negative hepatoid adenocarcinoma. The goal is to see if this approach can shrink tumors and improve outcomes. About 30 participants will receive the treatment, then undergo surgery, followed by more treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOID ADENOCARCINOMA OF STOMACH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.